How do neutrophil extracellular traps (NETs) contribute to the pathogenesis of drug‑induced lupus, especially with medications like hydralazine and procainamide?

NETs Contribute to Drug-Induced Lupus Through Direct Induction by Hydralazine and Procainamide via Oxidative and Calcium-Dependent Pathways

Hydralazine and procainamide directly trigger neutrophil extracellular trap (NET) formation through distinct but overlapping mechanisms—procainamide via muscarinic receptor engagement and hydralazine through intracellular calcium modulation—both requiring NADPH oxidase and PAD4 activation, which exposes nuclear autoantigens (histones, DNA) that drive the autoimmune response characteristic of drug-induced lupus. 1

Mechanistic Pathways of Drug-Induced NET Formation

The pathogenesis involves a two-step process where lupus-inducing medications are first biotransformed by activated neutrophils into reactive metabolites, then trigger aberrant NET formation:

Neutrophil-Mediated Drug Transformation

• Myeloperoxidase-dependent oxidation: Both hydralazine and procainamide require transformation by myeloperoxidase (released during neutrophil respiratory burst) in the presence of H₂O₂ to become cytotoxic products 2, 3
• This oxidative transformation is a common denominator linking structurally diverse lupus-inducing drugs—their shared capacity to serve as myeloperoxidase substrates correlates directly with their ability to induce lupus in vivo 2
• The reactive metabolites (e.g., procainamide-hydroxylamine) are the actual pathogenic agents, not the parent drugs 3

NET Formation Mechanisms

Both drugs trigger NETosis through NADPH oxidase and PAD4-dependent pathways 1, but via different upstream triggers:

• Procainamide: Engages muscarinic receptors on neutrophils, initiating signaling cascades that activate NADPH oxidase
• Hydralazine: Modulates calcium release from intracellular stores, leading to PAD4 activation and histone citrullination 4, 1
• Both pathways converge on chromatin decondensation and NET release containing nuclear proteins, DNA, and histones 4

Critical distinction: Minocycline and clozapine (medications less commonly associated with drug-induced autoimmunity) do not significantly induce NET formation, supporting the specificity of this mechanism 1

Autoantigen Exposure and Autoimmunity Development

NET Protein Cargo as Autoantigens

The NETs induced by hydralazine and procainamide display distinct protein cargo, particularly in histone content 1, which directly correlates with the autoantibody specificity observed in drug-induced lupus:

• IgG autoantibodies target histone H1 and the (H2A-H2B)-DNA complex in most patients with procainamide- and hydralazine-induced lupus 3
• The H3-H4 tetramer remains largely non-antigenic 3
• IgM autoantibodies react with DNA-free H3-H4 tetramer and H1, especially in hydralazine-induced cases, suggesting autoimmunization with non-native chromatin forms 3

Impaired NET Clearance

While the provided evidence shows these drugs do not significantly impair NET degradation by serum nucleases 1, the FDA label for hydralazine explicitly warns that the drug-induced lupus syndrome can produce glomerulonephritis, and "symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later" 5. This suggests that:

• The sheer volume of NET formation may overwhelm normal clearance mechanisms
• Chronic exposure creates a persistent autoantigen reservoir
• Anti-histone antibodies are more frequently found in drug-induced SLE 6, distinguishing it from idiopathic lupus

Clinical Implications and Monitoring

FDA-Mandated Surveillance

The FDA label for hydralazine specifically requires 5:

• Complete blood counts and antinuclear antibody (ANA) titer determinations before and periodically during prolonged therapy
• Testing indicated if patients develop arthralgia, fever, chest pain, continued malaise, or unexplained symptoms
• A positive ANA titer requires careful risk-benefit assessment of continuing hydralazine therapy

Distinguishing Drug-Induced from Idiopathic Lupus

Key differentiating features 6:

• Anti-histone antibodies are the hallmark of drug-induced lupus (present in most cases) but less common in idiopathic SLE
• Anti-dsDNA antibodies are typically negative in drug-induced lupus, unlike idiopathic SLE where they are diagnostic and used for monitoring 6
• Drug-induced lupus typically resolves upon drug discontinuation, though this may take months and occasionally requires corticosteroid treatment 5
• Absence of cirrhosis at presentation favors drug-induced over other autoimmune liver manifestations 7

Pathogenic Cascade Summary

The complete mechanistic pathway:

1. Drug exposure → Neutrophil activation and myeloperoxidase release
2. Oxidative transformation → Reactive drug metabolites (e.g., procainamide-hydroxylamine)
3. Receptor/calcium signaling → Muscarinic receptor engagement (procainamide) or calcium mobilization (hydralazine)
4. NADPH oxidase activation → ROS generation required for NET formation 4, 1
5. PAD4 activation → Histone citrullination and chromatin decondensation 4, 1
6. NET release → Exposure of modified nuclear autoantigens (histones, DNA)
7. Autoantibody production → IgG anti-histone and anti-(H2A-H2B)-DNA antibodies 3
8. Immune complex formation → Tissue deposition and inflammation
9. Clinical lupus syndrome → Arthralgia, serositis, glomerulonephritis 5

Important Caveat

The FDA warns that in some patients, hydralazine may produce a clinical picture "simulating systemic lupus erythematosus including glomerulonephritis" and should be discontinued unless benefit-risk determination requires continued therapy 5. Long-term steroid treatment may be necessary even after discontinuation 5, indicating that NET-mediated autoimmunity can establish self-perpetuating immune responses in susceptible individuals.